论文部分内容阅读
目的:探讨奥美拉唑联合阿莫西林克拉维酸钾治疗萎缩性胃炎的临床研究。方法:选取2014年3月至2016年3月紫金县蓝塘中心卫生院收治的萎缩性胃炎患者80例,按随机数字法分为观察组40例和对照组40例。给予对照组口服法莫替丁分散片治疗,观察组给予奥美拉唑联合阿莫西林克拉维酸钾治疗。观察比较两组患者的临床症状缓解情况、临床效果及不良反应,并在结束治疗40 d后对患者行14C-尿素呼气试验(14C-UBT)检测,对比两组患者Hp转阴情况。结果:两组患者治疗总有效率分别为95.0%、72.5%,观察治疗总有效率明显较对照组高,差异具有统计学意义(P<0.05);两组不良反应发生率5.0%,22.5%,观察组不良发应发生率显著较对照组低,差异具有统计学意义(P<0.05);观察组Hp转阴率87.5%显著高于对照组(62.5%),差异具有统计学意义(P<0.05)。结论:奥美拉唑联合阿莫西林克拉维酸钾用药方案在萎缩性胃炎临床治疗中取得理想的疗效,有效改善患者临床症状及清除Hp,不良反应少,具有较高的安全性。
Objective: To investigate the clinical study of omeprazole combined with amoxicillin and clavulanate in the treatment of atrophic gastritis. Methods: From March 2014 to March 2016, 80 patients with atrophic gastritis treated in Lan Tong Central Hospital of Zijin County were selected and divided into observation group (40 cases) and control group (40 cases) by random number method. The control group was treated with famotidine dispersible tablets, and the observation group was treated with omeprazole combined with amoxicillin and clavulanate potassium. Clinical symptoms and adverse reactions were observed and compared between the two groups. 14C-urea breath test (14C-UBT) was performed on the patients 40 days after the end of treatment, and Hp negative conversion was compared between the two groups. Results: The total effective rates of the two groups were 95.0% and 72.5% respectively. The total effective rate of observation and treatment was significantly higher than that of the control group (P <0.05). The incidence of adverse reactions in both groups was 5.0% and 22.5% (P <0.05). The negative conversion rate of Hp in observation group was significantly higher than that in control group (87.5% vs 62.5%, P <0.05), and the difference was statistically significant (P <0.05). The incidence of adverse reactions in observation group was significantly lower than that in control group <0.05). Conclusion: The combination of omeprazole and amoxicillin-potassium clavulanate in the clinical treatment of atrophic gastritis can effectively improve the clinical symptoms and eliminate Hp in patients with atrophic gastritis with less adverse reactions and higher safety.